Helix BioPharma Corp. (TSX:HBP)

Helix BioPharma Ratios and Metrics

Market cap in millions CAD. Fiscal year is August - July.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 24, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Market Cap	126	79	56	42	33	117
Market Cap Growth	283.70%	40.75%	34.21%	28.68%	-72.14%	63.19%
Enterprise Value	126.35	79.62	55.29	41.2	29.39	115.16
Last Close Price	1.69	1.07	1.15	1.05	0.95	4.15
PE Ratio	-	-11.89	-5.48	-6.56	-4.75	-13.83
PB Ratio	8.20	5.09	-626.39	-49.77	102.32	-84.09
P/FCF Ratio	-	-20.70	-10.77	-7.59	-5.01	-12.59
P/OCF Ratio	-	-20.71	-10.80	-7.60	-5.01	-12.59
EV/EBITDA Ratio	-	-14.78	-5.99	-6.53	-4.88	-12.89
EV/EBIT Ratio	-	-14.75	-5.98	-6.51	-4.87	-12.61
EV/FCF Ratio	-	-20.77	-10.57	-7.44	-4.52	-12.38
Debt / Equity Ratio	0.02	0.02	0	0	0	-1.14
Debt / EBITDA Ratio	-0.09	-0.06	-	-	-0.41	-0.40
Debt / FCF Ratio	-0.10	-0.09	-	-	-0.38	-0.39
Net Debt / Equity Ratio	0.02	0.02	12.01	0.96	-2.46	-0.03
Net Debt / EBITDA Ratio	-0.08	-0.05	0.12	0.13	0.13	0.00
Net Debt / FCF Ratio	-0.09	-0.07	0.21	0.15	0.12	0.00
Quick Ratio	0.02	0.06	0.72	0.46	1.03	1.01
Current Ratio	0.04	0.13	0.92	0.53	1.08	1.04
Return on Equity (ROE)	-26.70%	-67.18%	1983.73%	2396.19%	1222.16%	-1012.34%
Return on Assets (ROA)	-21.93%	-53.20%	-733.84%	-265.80%	-154.95%	-203.57%
Return on Invested Capital (ROIC)	-26.07%	-73.50%	1011.94%	1129.64%	667.03%	763.46%
Return on Capital Employed (ROCE)	-26.23%	-69.66%	1976.26%	2405.32%	-2368.63%	-575.73%
Earnings Yield	-3.33%	-8.41%	-18.26%	-15.24%	-21.05%	-7.23%
FCF Yield	-	-4.83%	-9.28%	-13.18%	-19.94%	-7.94%
Buyback Yield / Dilution	-1.59%	-3.53%	-9.77%	-9.88%	-19.01%	-3.04%

Updated Jan 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.